Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominique P Germain

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Kidney International|September 15, 2023
Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic targetDominique P Germain
Journal De La Societe De Biologie|October 4, 2002
[Lysosomes and lysosomal storage diseases]Dominique P Germain
Clinical Therapeutics|December 6, 2007
Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapyDominique P Germain
Presse Medicale (Paris, France : 1983)|June 5, 2007
[Genetics of Fabry disease: diagnostic and therapeutic implications]Dominique P Germain
Journal De La Societe De Biologie|October 4, 2002
[Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations]Dominique P Germain
Expert Opinion on Investigational Drugs|October 22, 2002
Fabry disease: recent advances in enzyme replacement therapyDominique P Germain
Annals of Vascular Surgery|May 23, 2002
Clinical and genetic features of vascular Ehlers-Danlos syndromeDominique P Germain
La Revue Du Praticien|December 5, 2018
[Joint hypermobility: when to evoke Ehlers-Danlos syndrome]?Dominique P Germain
Current Treatment Options in Cardiovascular Medicine|March 15, 2006
The vascular Ehlers-Danlos syndromeDominique P Germain
Orphanet Journal of Rare Diseases|May 11, 2017
Pseudoxanthoma elasticumDominique P Germain
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Kidney International|September 15, 2023
Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic targetDominique P Germain
Journal De La Societe De Biologie|October 4, 2002
[Lysosomes and lysosomal storage diseases]Dominique P Germain
Clinical Therapeutics|December 6, 2007
Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapyDominique P Germain
Presse Medicale (Paris, France : 1983)|June 5, 2007
[Genetics of Fabry disease: diagnostic and therapeutic implications]Dominique P Germain
Journal De La Societe De Biologie|October 4, 2002
[Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations]Dominique P Germain
Expert Opinion on Investigational Drugs|October 22, 2002
Fabry disease: recent advances in enzyme replacement therapyDominique P Germain
Annals of Vascular Surgery|May 23, 2002
Clinical and genetic features of vascular Ehlers-Danlos syndromeDominique P Germain
La Revue Du Praticien|December 5, 2018
[Joint hypermobility: when to evoke Ehlers-Danlos syndrome]?Dominique P Germain
Current Treatment Options in Cardiovascular Medicine|March 15, 2006
The vascular Ehlers-Danlos syndromeDominique P Germain
Orphanet Journal of Rare Diseases|May 11, 2017
Pseudoxanthoma elasticumDominique P Germain
Pageof 14